The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this survey is to confirm the safety of Suglat Tablets when used in the elderly.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Ipragliflozin

Criteria

Inclusion Criteria:

• type 2 diabetes who used Suglat Tablets within 3 months from its launch

Exclusion Criteria:

• off-label use patients